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EndometriumProkineticins and their receptors are expressed in various cellular compartments in human endometrium,
with prokineticin 1 (PROK1) showing a dynamic pattern of expression across the menstrual cycle and during
pregnancy. Previous studies suggest that PROK1 can play an important role in implantation and early
pregnancy by inducing vascular remodeling and increasing vascular permeability. Here we demonstrate that
PROK1 induces the expression of IL-8, a chemokine with angiogenic properties, in endometrial epithelial
Ishikawa cells stably expressing prokineticin receptor 1 and in human ﬁrst trimester decidua. We also show
that IL-8 promoter activity is induced by PROK1 and that this requires the presence of AP1 and NFAT motifs.
The role of calcineurin/NFAT signaling pathway is conﬁrmed by the use of speciﬁc chemical inhibitors.
Additionally, PROK1 induces the expression of the regulator of calcineurin 1 isoform 4 (RCAN1-4) via the
calcineurin/NFAT pathway. A modulatory role for RCAN1-4 is demonstrated by RCAN1-4 overexpression
which results in the inhibition of PROK1-induced IL-8 expression whereas reduction in RCAN1-4 endogenous
expression results in an increase in PROK1-induced IL-8 production. Our ﬁndings show that in endometrial
cells PROK1 can activate the calcineurin/NFAT pathway to induce IL-8 expression and that this is negatively
modulated by the induction of expression of RCAN1-4.© 2009 Elsevier B.V.Open access under CC BY license.1. Introduction
The prokineticins, prokineticin 1 (PROK1) and prokineticin 2
(PROK2), are two secreted factors that have been described to play
roles in multiple processes such as intestinal contraction [1], vascular
function [2], hematopoiesis [3,4] and the development of the olfactory
and GnRH systems [5,6]. These effects are induced via binding to and
activation of their cognate receptors, two G protein-coupled receptors
called prokineticin receptor 1 (PROKR1) and prokineticin receptor 2
(PROKR2). Both receptors bind to PROK1 and PROK2 with similar
afﬁnities [7,8] and studies in vitro have shown they can couple to Gi
and Gq proteins [2,7,8] and activate intracellular signaling molecules
such as PLC, ERK, Akt and eNOS [2,7,9,10].
Prokineticins and their receptors are widely expressed in both
male and female reproductive systems [11]. In the uterus, the
expression of prokineticins and their receptors has been described
with only PROK1 showing a temporal pattern of expression across
the menstrual cycle; with maximal levels of expression observed
during the mid secretory phase [12,13]. PROK1 has been localized to+44 131 2426231.
our).
nd Developmental Sciences,
 license.endometrial glandular and luminal epithelium, stromal and
endothelial cells as well as myometrial vascular endothelium and
smooth muscle [12,13]. In addition, expression of PROK1 and
PROKR1 is elevated in ﬁrst trimester decidualized endometrium
compared to non-pregnant endometrium [10]. This pattern of
expression suggests that PROK1 could have an important role in
the physiology of the non-pregnant and pregnant endometrium. The
central role that angiogenesis plays in endometrial physiology
together with the angiogenic properties reported for prokineticins
lead us to investigate the possible role of prokineticins in the
induction of expression of angiogenic factors. IL-8 is a factor that
belongs to the CXC chemokine family, whose known actions include
neutrophil chemotactic/activating and T-cell chemotactic activity
[14], as well as chemotaxis and proliferation of endothelial cells in
vitro and angiogenesis in vivo [15]. Previous studies have demon-
strated that PROK1 induced the expression of IL-8 in monocytes [16]
and third trimester placenta [17]. In the present study we
investigated the role of PROK1 in the modulation of IL-8 expression
and secretion. We conﬁrmed that activation of PROKR1 by PROK1 in
human endometrial epithelial cells resulted in the induction of
expression of IL-8 and we demonstrated that this induction occurred
via the activation of the calcineurin/nuclear factor of activated T-
cells (NFAT) signaling pathway. We also showed that PROK1 via the
same pathway induced the expression of the regulator of calcineurin
1 isoform 4 (RCAN1-4), an endogenous modulator of the calcineurin
1316 D. Maldonado-Pérez et al. / Biochimica et Biophysica Acta 1793 (2009) 1315–1324signaling pathway. Expression of RCAN1-4 negatively modulated the
expression of IL-8 induced by PROK1.
2. Materials and methods
2.1. Reagents
DMEM nutrient mixture F-12 culture mediumwas purchased from
Invitrogen (Paisley, UK). YM-254890 was kindly donated by Astellas
Pharma Inc (Tsukuba, Japan). NF-κB SN50 cell permeable inhibitory
peptide was purchased from Biomol International (Exeter, UK).
Cyclosporin A and Inhibitor of NFAT-Calcineurin Association-6 (Inca-
6) were purchased from Calbiochem (Nottingham, UK). Flag-tagged
NFATc1 plasmid construct was a kind gift from Dr Tania N. Crotti (Beth
Israel Deaconess Medical Center, Boston, MA).
2.2. Cell culture
Ishikawa endometrial adenocarcinoma cells were obtained from
the European Collection of Cell Culture (Wiltshire, UK). Stable PROKR1
transfectant cells were designed and characterized as described before
[10]. These cells were cultured in DMEM/F-12 cultured medium
supplementedwith 10% fetal bovine serum and amaintenance dose of
200 μg/ml of G418 antibiotic.
2.3. Tissue collection
First trimester decidua (9–12 wk, n=7) was collected from
women undergoing elective ﬁrst trimester surgical termination of
pregnancy. Ethical approval was obtained from Lothian Local Research
Ethics Committee, and written informed consent obtained from all
patients before tissue collection.
2.4. Angiogenesis array
The human angiogenesis antibody array I (RayBiotech, Inc.,
Norcross, GA) was used according to the manufacturer's instructions.
Brieﬂy, the membranes were incubated with 2 ml blocking buffer for
30 min, followed by 2 h incubation with 1 ml of conditioned medium
collected from cultured Ishikawa PROKR1 cells treated with or
without 40 nM PROK1 for 8 h. After washing, the membranes were
incubated overnight with 1 ml of biotin-conjugated antibodies
solution. The membranes were then washed, incubated with 1 ml
HRP-conjugated streptavidin for 2 h and washed. Subsequently the
membranes were incubated in detection buffer mix for 2 min and
exposed to X-ray ﬁlm for 5–30 s. Densitometric analysis was
performed using the ImageQuant TL software (GE Healthcare, Little
Chalfont, UK).
2.5. Taqman quantitative RT-PCR
Total RNA was extracted from cells and tissues using Total RNA
Isolation Reagent (Abgene, Epsom, UK). Quantiﬁed RNA samples were
reverse transcribed and quantitative RT-PCR was performed as
described before [18] using the following primers and probes:
RCAN1: forward: 5′-CGCCAAATCCAGACAAGCA-3′; reverse: 5′-
CGCATCTTCCACTTGTTTCCA-3′ and probe: 5 ′-FAM-TCTCCC
CTCCCGCCTCTCCG-3′; RCAN1-4: forward: 5′-GAAAGTGAAAC-
CAGGGCCAAA-3′; reverse: 5′-GCTGGAGCCTGGCATCTG-3′ and probe:
5′-FAM-TCAGAATAAACTTCAGCAACCCCTTCTCCG-3′; IL-8: forward:
5′-CTGGCCGTGGCTCTCTTG-3′; reverse: 5′-TTAGCACTCCTTGG-
CAAAACTG-3′ and probe: 5′-FAM-CCTTCCTGATTTCTGCAGCTCTGTGT-
GAA-3′. Custom primers and probes for RCAN, calcineurin and NFAT
different isoforms were purchased from Applied Biosystems (Foster
City, CA). The expression of analyzed genes was normalized for RNA
loading using 18S rRNA or GAPDH as internal standards.2.6. Immunohistochemistry
Tissue section dual immunoﬂuorescent histochemistry was carried
out as previously described [17], using a goat anti-IL-8 antibody (1:20;
R&D Systems Europe Ltd., Abingdon, UK) and a rabbit anti-PROKR1
antibody (1:100; MBL, Woburn, MA).
2.7. Western blot analysis
Protein concentration of cell lysates was quantiﬁed using Bio-Rad
protein assay kit (Bio-Rad Laboratories, Hemel Hempstead, UK). After
resolving and blotting, membranes were incubated overnight at 4 °C,
with a rabbit anti RCAN-1 antibody (1:5000), a kind gift from Dr Erik
W. Bush (Myogen, Inc, Westminster, CO), together with a mouse anti
β-actin antibody (1:800) (Santa Cruz Biotechnology, Santa Cruz, CA).
The following day, cells were washed and incubated with goat anti-
rabbit Alexaﬂuor 680 (1:5000; Invitrogen) and goat anti-mouse
IRDye™ 800 (1:5000; Rockland, Gilbersville, PA) for 60 min at room
temperature. Blots were visualized and the protein immunoreactivity
quantiﬁed using an Odyssey infrared imaging system (LI-COR, Cam-
bridge, UK). RCAN1 relative density was calculated by dividing the
value obtained for RCAN1 by the value obtained for β-actin and
expressed as fold above vehicle controls.
2.8. Secreted IL-8 quantiﬁcation
Secreted IL-8 was quantiﬁed using an in-house enzyme linked
immunosorbent assay (ELISA) described previously [19]. A matched
pair of capture and biotinylated labeled detection antibodies for IL-8
and recombinant IL-8 were used (R&D Systems, Oxford, UK).
2.9. Luciferase reporter assay
pNF-κB-Luc and pAP1-Luc vectors were purchased from Clontech
(Mountain View, CA). RCAN1-4 promoter reporter plasmids and
NFAT4-Luc were kindly donated by Dr Takashi Minami (University of
Tokyo, Tokyo, Japan) [20]. The IL-8 promoter reporter constructs were
kindly donated by Dr Allan R. Brasier (Department of Internal
Medicine, University of Texas Medical Branch, Galveston, Texas) [21].
Ishikawa PROKR1 cells were plated in 24 well plates at a density of
60,000 cells/well. After 24 h of incubation, cells were co-transfected
with one of the different promoter reporter plasmids used in
combination with a Renilla luciferase internal control vector pRL-TK
(Promega, Southampton, UK; 10:1 promoter reporter plasmid:pRL-
TK) using Superfect transfection reagent (QIAGEN, Crawley, UK)
following manufacturer's guidelines. The following day the cells were
serum starved for 16 h. Cells were then treated in serum free media.
After this, cells were lysed and the activity of both ﬁreﬂy and Renilla
luciferase on each sample was determined using the dual luciferase
assay kit (Promega).
2.10. RCAN1-4 adenovirus infection
The cDNA of RCAN1-4 (ORIGENE, Rockville, MD) was excised with
EcoRI and SmaI and fused to EcoRI and SmaI restricted pDC316 shuttle
vector (Microbix Biopharmaceuticals, Toronto, Canada) to create
pDC316-RCAN1-4.
HEK 293 cells (ATCC CRL 1573) were cultured in MEM+Glutamax
medium (Invitrogen) containing 10% FCS and 1% Penicillin/Strepto-
mycin. Cells were transfected with 0.5 μg pDC316-RCAN1-4 and 1.5 μg
adenoviral genomic plasmid pBHGloxΔ E1,3 Cre (Microbix) using
TransIT-293 as per manufacturer's instructions (Mirus Bio Corp,
Madison, WI). Adenoviral plaques were harvested 10–14 days later
and virus released by 3 × freeze/thaw cycles. Clonal plaques were
obtained by serial dilution and infection of 80% conﬂuent HEK 293
cells overlaid 5 h post inoculation with 0.5% SeaPlaque Agarose (FMC
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8–12 days later, inoculated into a T75 ﬂask and incubated until 70%–
80% cytopathic effect (CPE) was observed. This ﬁrst seed was
inoculated intomultiple ﬂasks and harvestedwhen CPE was apparent.
RCAN1-4 Adenovirus was puriﬁed, concentrated, aliquoted and stored
at −80 °C (Vivapure AdenoPACK 100 puriﬁcation kit; Sartorius AG,
Goettingen, Germany). Titers were determined using the AdenoX
Rapid titer kit (CloneTech). Yields of in excess of 1×1010 IFU/ml were
routinely obtained.
Ishikawa PROKR1 cells were plated in 6 well plates at a density of
200,000 cells/well. After 24 h of incubation, cells were washed with
PBS and 1 ml of fresh medium containing 5 adenovirus pfu/plated cell
was added to each well. Cells were incubated for another 24 h and
serum starved overnight before treatment with 40 nM PROK1.
2.11. Lentivirus shRNA gene silencing
A short hairpin RNA (shRNA) lentivirus, previously described
[22], was used to knock down the expression of RCAN1. Brieﬂy,
Ishikawa PROKR1 cells were plated in 12 well plates at a density of
80,000 cells/well. After 24 h of incubation, cells were infected with
virus-containing media at a 1:10 dilution of virus to target cell
media and 0.6 μg/ml Polybrene. The day after, medium was replaced
with fresh serum-containing medium and 48 h post-infection, the
cells which were serum starved overnight, were treated with 40 nM
PROK1.
2.12. Statistical analysis
The data in this study was analyzed by t test, ANOVA or Kruskal–
Wallis nonparametric test using Prism 4.0c (Graph Pad, San Diego,
CA).
3. Results
3.1. PROK1 induces the expression of IL-8 in human endometrial
Ishikawa cells and ﬁrst trimester decidua
In order to investigate the potential role of PROK1 on the induction
of angiogenic factors in endometrial cells, we made use of a human
endometrial adenocarcinoma Ishikawa cells [23], stably expressing
PROKR1 [10]. Conditioned medium collected from cells treated with
40 nM PROK1 or vehicle for 8 h was used in an angiogenesis protein
array. The array showed that the chemokines: GRO, IL-6, IL-8 and
MCP-1 were upregulated by more than two-fold following treatment
with PROK1, with IL-8 showing the highest upregulation (N8 fold
increase) (Fig. 1A).
We decided to investigate in more detail the induction of IL-8 by
PROK1 based on documented expression of this chemokine in the
non-pregnant and pregnant uterus [24] and its known roles in
angiogenesis [15]. A previous study in our group showed the induction
of IL-8 mRNA by PROK1 in Ishikawa PROKR1 cells by gene array
analysis [10]. In agreement with these previous results, time courses
of IL-8 mRNA levels (Fig. 1B) and IL-8 protein secretion (Fig. 1C) in
response to treatment with 40 nM PROK1 conﬁrmed that PROK1
treatment increased IL-8 mRNA and protein (pb0.01). Similarly,
Ishikawa PROKR1 cells transfected with a construct coding for the
promoter region of IL-8 linked to the luciferase reporter gene [21] and
treated with 40 nM PROK1 showed a signiﬁcant induction of IL-8
promoter activity (Supplementary Fig. 1).
We also tested the induction of IL-8 by PROK1 in ﬁrst trimester
decidua explants. Treatment with 40 nM PROK1 induced a
signiﬁcant increase in IL-8 expression (pb0.05; Fig. 1D). In addition,
dual ﬂuorescent immunohistochemical analysis showed that
PROKR1 and IL-8 are co-expressed in the epithelium of ﬁrst
trimester decidua (Fig. 1E).3.2. PROK1 induces activation of IL-8 promoter through AP1 and NFAT
To identify promoter regions involved in the induction of
expression of IL-8 by PROK1, truncated versions of the IL-8 promoter
construct were used. A considerable reduction in promoter activity
was observed when the promoter was truncated down to −99
nucleotides of the 5′ ﬂanking region (pb0.05). A further reduction in
promoter activity was observed in the −54 nucleotides truncated
construct which only contains the IL-8 TATA box (pb0.05; Fig. 2A).
These results suggested that the region between −132 and −54
nucleotides was required for IL-8 gene activation by PROK1.
Site directed mutated versions of the −162 IL-8 promoter at
consensus binding sequences for AP-1 (−125 to −119 nucleotides)
and NFAT (−80 to−75 nucleotides) showed that these binding sites
are required for PROK1-induced transcription of IL-8 (Fig. 2A). The
NFAT binding site in the IL-8 promoter is part of a κB-like consensus
sequence that can also bind NF-κB. In order to determine if NF-κB was
involved in the activation of IL-8 promoter in Ishikawa PROKR1 cells
wemade use of the NF-κB inhibitory peptide SN50 (100 μg/ml) which
did not reduce the activity of IL-8 promoter induced by PROK1 (Fig.
2B). Also, Ishikawa PROKR1 cells transfected with the pNF-κB-Luc
vector (Promega) and treated with 40 nM PROK1 did not induce NF-
κB-driven luciferase activity. In contrast, luciferase reporter constructs
containing NFAT or AP1 binding sites were readily activated by
treatment with PROK1 (pb0.05; Fig. 2C).
3.3. The calcineurin signaling pathway is involved in PROK1-induced
expression of IL-8
Having identiﬁed that NFATc transcription factors may be
important in IL-8 induction, we quantiﬁed the mRNA expression of
NFATc isoforms in Ishikawa PROKR1 cells. Expression of NFATc1,
NFATc2, NFATc3 and NFATc4 message was detected in these cells.
Treatment with 40 nM PROK1 did not induce a signiﬁcant change in
the expression of NFATc isoforms (Supplementary Fig. 2).
We subsequently analysed the role of the calcineurin/NFATc path-
way in IL-8 induction by PROK1.We co-transfected cells with anNFATc1
construct and the IL-8 promoter-luciferase construct into Ishikawa
PROKR1 cells. Transfection of the NFATc1 construct induced an increase
in IL-8 promoter activity in a dose dependent manner (Fig. 2D).
In addition, the use of chemical inhibitors conﬁrmed the role of the
calcineurin signaling pathway in the induction of IL-8 expression in
Ishikawa PROKR1 cells. Pretreatment of Ishikawa PROKR1 cells with
chemical inhibitors for Gq (YM254890), calcineurin (cyclosporine A)
and NFAT (Inca-6), as well as an extracellular calcium chelator (EGTA)
resulted in a signiﬁcant inhibition of PROK1-induced expression of IL-
8 mRNA (pb0.001). These inhibitors did not signiﬁcantly change the
basal expression of IL-8 (data not shown). In contrast, the use of an
NF-κB inhibitory peptide (SN50) induced an increase in the expres-
sion of IL-8 induced by PROK1 (Fig. 2E), and basal expression of IL-8
was also signiﬁcantly induced by SN50 (data not shown). On the other
hand, the use of an ionophore (ionomycin), which allows extracellular
calcium entry to the cytoplasm, resulted in a similar induction of IL-8
mRNA to that induced by PROK1 giving further support to the role of
the calcium-dependent calcineurin signaling pathway (Fig. 2F).
3.4. PROK1 induces the expression of the calcineurin negative modulator
RCAN1
Having identiﬁed that the calcineurin signaling pathway is
required for the induction of expression of IL-8 by PROK1, we then
explored the induction by PROK1 of the regulator of calcineurin 1
(RCAN1), also known as Down syndrome critical region gene 1
(DSCR1) or Adapt 78 [25].
Treatment of Ishikawa PROKR1 cells with 40 nM PROK1 resulted in
rapid induction of RCAN1 mRNA (pb0.001; Fig. 3A). The use of
Fig.1. PROK1 induces the expression of IL-8 in Ishikawa PROKR1 cells and human ﬁrst trimester decidua. (A) Conditionedmedium from Ishikawa PROKR1 cells treatedwith vehicle or
40 nM PROK1 for 8 h was tested for the expression of angiogenic factors using the human angiogenesis antibody array I. Expression of GRO, IL-6, IL-8 and MCP-1 was upregulated by
more than 2 fold by treatment with PROK1. (B) Ishikawa PROKR1 cells treated with 40 nM PROK1 showed a signiﬁcant increase in the expression of IL-8 mRNA but not control treated
cells. (C) Similarly, IL-8 protein secretion was signiﬁcantly increased by 40 nM PROK1 treatment. (D) Human ﬁrst trimester decidua explants treated with 40 nM PROK1 showed a
signiﬁcant increase in the expression of IL-8 mRNA at 24 h. (E) Flouresent immuno histochemistry showed that PROKR1 (red) and IL-8 (green) co-immunolocalized (yellow) in
glandular epithelium of ﬁrst trimester human decidua. Data in B, C, and D are presented as mean±S.E. of n=3–7 experiments ⁎pb0.05, ⁎⁎pb0.01, ⁎⁎⁎pb0.001. Control = vehicle
treatment of Ishikawa PROKR1 cells.
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expression of isoform 4 (pb0.001) but not isoforms 1 nor 2 (Fig. 3B).
RCAN1 isoform 4 (RCAN1-4) is an endogenous modulator of the
calcineurin signaling pathway and previous studies have identiﬁed
that PROK1 can induce expression of RCAN1 by gene array analysis
[10]. Similarly, treatment of ﬁrst trimester decidua with 40 nM PROK1
resulted in a signiﬁcant increase in the expression of RCAN1-4 at 2 h
(Supplementary Fig. 3).
Also, treatment of Ishikawa PROKR1 cells with 40 nM PROK1
resulted in the induction of expression of RCAN1-4 protein (28 kDa;
pb0.001) [26]. In contrast RCAN1 isoform 1 (38 kDa band) [26]
expression was not increased by PROK1 treatment (Fig. 3C).
Making use of a promoter-luciferase construct, we observed that
PROK1 induced the activity of RCAN1-4 promoter (pb0.01; Fig. 3D). It
has been reported that RCAN1-4 promoter region contains 15 NFAT
binding sites [27]. To investigate the role of NFAT in the modulation ofthe expression of RCAN1-4 induced by treatment with PROK1, we
made use of truncated versions of RCAN1-4 promoter. The results
showed that PROK1-induced RCAN1-4 promoter activation was only
signiﬁcantly impaired when the promoter was truncated down to
−166 nucleotides (pb0.001). This truncated version of RCAN1-4
promoter contains some NFATc putative binding sites but they were
not sufﬁcient for activation of gene transcription (Fig. 3E). We then
made use of a −350 nucleotides RCAN1-4 promoter construct
containing a point mutation in one of the NFAT binding sites
(−350ΔNFAT) to test whether NFATc binding to this promoter is
involved in the activation of RCAN1-4. This promoter construct
showed a signiﬁcantly reduced activity in comparison to −350 wild
type (pb0.01; Fig. 3E).
The use of chemical inhibitors conﬁrmed that the calcineurin/
NFAT signaling pathway is involved in the induction of RCAN1-4.
Inhibitors for Gq (YM254890), calcineurin (cyclosporine A) and NFAT
Fig. 2. PROK1 induces IL-8 via NFATand AP1 but not NF-κB. (A) The use of truncated versions of thewild type (wt) IL-8 promoter-luciferase construct allowed the identiﬁcation of the
region between−132 nucleotides and−54 nucleotides to be important for activation by treatmentwith PROK1. Furthermore, the use of−162 truncated constructs containing point
mutations identiﬁed AP1 and NFAT binding sites to be required for IL-8 promoter activation. Data are presented as fold increase of PROK1 treated cells (6 h) above control treated
cells. (B) PROK1-induced IL-8 promoter activity at 6 h was not inhibited by an NF-κB inhibitory peptide (SN50, 100 μg/ml). Data are presented as percentage of RLU relative to PROK1
treated cells. (C) The use of luciferase constructs containing speciﬁc binding sites for NFAT, NF-κB and AP1 show that PROK1 treatment for 6 h induced activation of the NFAT and AP1
constructs but not NF-κB. (D) PROK1-induced IL-8 promoter activity was increased by transiently transfecting Ishikawa PROKR1 cells with an NFATc1 plasmid. The increase in
promoter activity induced by NFATc1 plasmid was dose dependent. (E) The induction of IL-8 mRNA by PROK1 at 6 h could be signiﬁcantly inhibited by the use of Gαq/11 inhibitor
(YM-254890, 100 nM), calcium chelator (EGTA, 1.5 mM), calcineurin inhibitor (cyclosporine, 1 μM), and NFAT inhibitor (Inca-6, 40 μM). In contrast, a signiﬁcant increase in IL-8
mRNA expression was observed when cells were pretreated with NF-κB inhibitory peptide (SN50, 100 μg/ml). Data are presented as percentage of mRNA expression relative to
PROK1 treated cells. (F) Treatment of Ishikawa PROKR1 cells with an ionophore (ionomycin, 2 μM) for 2 h resulted in an increase in IL-8 mRNA similar to that induced by PROK1. Data
are presented as percentage of mRNA expression relative to PROK1 treated cells. All data are presented as mean±S.E. of n=3–4 experiments. ⁎pb0.05, ⁎⁎⁎pb0.001. Control =
vehicle treatment of Ishikawa PROKR1 cells.
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Fig. 3. RCAN1-4 expression is induced by PROK1 via activation of the calcineurin/NFAT pathway. (A) Treatment of Ishikawa PROKR1 cells with 40 nM PROK1 resulted in a rapid
increase in the expression of RCAN1 mRNA. (B) mRNA quantiﬁcation of the different isoforms of RCAN-1 show that PROK1 treatment for 2 h speciﬁcally induced mRNA expression of
isoform 4 of RCAN1. (C) Western blot analysis showed that protein levels of RCAN1 isoform 4 (28 kDa), but not isoform 1 (38 kDa), were upregulated by PROK1. The expression
of RCAN1-4 was normalized using β-actin as a loading control. C = vehicle and P = PROK1 treated cells. (D) RCAN1-4 promoter-luciferase construct was activated by treatment of
Ishikawa PROKR1 cells with 40 nM PROK1 but not by control treatment. (E) The use of truncated versions of the RCAN1-4 promoter-luciferase construct showed that the activity
of RCAN1-4 was reduced when the promoter was truncated between −350 and −166 nucleotides. A point mutation on one of the NFAT binding sites remaining on the −350
nucleotides truncated promoter (−350ΔNFAT) resulted in a signiﬁcant reduction in promoter activity. Data are presented as fold increase of PROK1 treated cells (6 h) above control
treated cells. (F) The use of Gαq/11 inhibitor (YM-254890, 100 nM), calcium chelator (EGTA, 1.5 mM), calcineurin inhibitor (cyclosporine, 1 μM), and NFAT inhibitor (Inca-6, 40 μM)
resulted in a signiﬁcant inhibition of PROK1-induced expression of RCAN1-4 mRNA after 6 h treatment. In contrast, no reduction in RCAN1-4 mRNA expression was observed with
NF-κB inhibitory peptide (SN50, 100 μg/ml). Data are presented as percentage of mRNA expression relative to PROK1 treated cells. All data are presented as mean±S.E. of n=3–5
experiments. ⁎pb0.05, ⁎⁎pb0.01, ⁎⁎⁎pb0.001. Control = vehicle treatment of Ishikawa PROKR1 cells.
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signiﬁcantly inhibited the expression of RCAN1-4 mRNA (pb0.001).
However, an NF-κB inhibitory peptide (SN50) did not have an effect
on RCAN1-4 expression (Fig. 3F). In contrast, the use of ionomycin
resulted in a similar induction of RCAN1-4 mRNA to that induced by
PROK1 (Supplementary Fig. 4).
3.5. RCAN1-4 overexpression inhibits PROK1-induced expression of IL-8
In order to investigate further the role of NFAT in the induction of
expression of IL-8 and the role of RCAN1-4 in this process, we
overexpressed RCAN1-4, which is known to bind to calcineurin and
inhibit activation of NFATc when overexpressed [28]. For this we usedFig. 4. Overexpression of RCAN1-4 results in downregulation of PROK1-induced expression
RCAN1-4 adenovirus showed an increased expression of this protein compared to cells infect
(P) for 1, 2 and 4 h. (B) Ishikawa PROKR1 cells overexpressing RCAN1-4 showed a signiﬁcant r
comparison to cell infected with an empty adenovirus. (C) IL-8 protein secretion induced by
empty adenovirus infected cells. Data are presented as percentage of protein expression r
overexpression did not affect PROK1-induced expression of LIF, a gene not known to be modu
promoter construct was also signiﬁcantly reduced by overexpression of RCAN1-4 at 8 h. (F)
reduced when RCAN1-4 was overexpressed in Ishikawa PROKR1 cells. Data represent the
treatment of Ishikawa PROKR1 cells.an adenoviral construct coding for RCAN1-4 that induced an increase
in expression of RCAN1-4 protein in infected Ishikawa PROKR1 cells
(Fig. 4A).
RCAN1-4 overexpression resulted in a signiﬁcant reduction in
PROK1-induced expression of IL-8 mRNA in Ishikawa PROKR1 cells
(pb0.001; Fig. 4B). In addition, the amount of IL-8 protein secreted
was also signiﬁcantly reduced (pb0.05; Fig. 4C). In order to determine
if the observed inhibitory effect of overexpressing RCAN1-4 was
speciﬁc, we looked at the effect of RCAN1-4 adenovirus on the
expression of leukemia inhibitory factor (LIF), a gene known to be
induced by PROK1 in Ishikawa PROKR1 cells [10] and that is not
known to be modulated via NFAT. No signiﬁcant reduction of PROK1-
induced LIF mRNA expression was observed in cells infected withof IL-8. (A) Western blot analysis showed that Ishikawa PROKR1 cells infected with an
edwith a control empty adenovirus. Cells were treated with vehicle (C) or 40 nM PROK1
eduction in the amount of IL-8 mRNA induced by treatmentwith 40 nM PROK1 for 8 h in
PROK1 was signiﬁcantly reduced in RCAN1-4 adenovirus infected cells in comparison to
elative to empty adenovirus infected cells treated with PROK1 for 8 h. (D) RCAN1-4
lated by the calcineurin/NFAT pathway. (E) PROK1-induced activation of IL-8-luciferase
Similarly, the activity of an NFAT-luciferase promoter construct at 6 h was signiﬁcantly
mean±S.E. of n=4 experiments. ⁎pb0.05, ⁎⁎pb0.01, ⁎⁎⁎pb0.001. Control = vehicle
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adenovirus (Fig. 4D).
In agreement with the above results, the activity of IL-8 promoter
in Ishikawa cells stimulated with PROK1 showed a signiﬁcant
reduction when RCAN1-4 was overexpressed (pb0.05; Fig. 4E). The
inhibitory effect of RCAN1-4 overexpression on activation of IL-8
promoter could be explained by the known role of RCAN1-4 as an
inhibitor of NFATactivation [28]. In order to test this, the activity of the
NFAT-luciferase promoter construct induced by treatmentwith PROK1
was measured in cells infected with empty or RCAN1-4 adenovirus.
Overexpression of RCAN1-4 produced a signiﬁcant reduction in the
activation of NFAT by PROK1 (pb0.01; Fig. 4F).Fig. 5. Inhibition of endogenous RCAN1-4 results in an increase in IL-8 induction by
PROK1. (A) Ishikawa PROKR1 cells infected with a lentivirus expressing an shRNA to
RCAN1 showed a signiﬁcant reduction in the expression of endogenous RCAN1-4 mRNA
compared to cells infected with a non target (NT) control lentivirus. (B) Reduction in
the expression of endogenous RCAN1-4 resulted in a signiﬁcant increase in the
expression of IL-8 mRNA induced after treatment with 4 nM PROK1 for 12 h. (C)
Secreted IL-8 protein was also higher in cells infected with RCAN1 shRNA lentivirus
compared to NT control infected cells after treatment with 4 nM PROK1 for 12 h. Data
are presented as percentage of protein expression relative to empty NTshRNA infected
cells treated with PROK1. All data are presented as mean±S.E. of n=3–4 experiments.
⁎pb0.05, ⁎⁎pb0.01, ⁎⁎⁎pb0.001. Control = vehicle treatment of Ishikawa PROKR1 cells.3.6. Inhibition of endogenous RCAN1-4 expression results in an increased
expression of PROK1-induced IL-8
In order to give further support to the role of RCAN1-4 as a negative
modulator of PROK1-induced expression of IL-8, we made use of an
shRNA lentiviral construct that targets RCAN1. Infection of Ishikawa
PROKR1 cells with RCAN1 shRNA lentivirus resulted in a reduction in
the expression of basal levels of endogenous RCAN1-4mRNA (pb0.01;
Fig. 5A, time 0 h). In addition, PROK1-induced increase in RCAN1-4
mRNA expression was signiﬁcantly reduced in RCAN1 shRNA infected
cells compared to non target control (NT) shRNA infected cells
(pb0.001; Fig. 5A, time 2 h). On the other hand, infection of cells with
RCAN1 shRNA resulted in an increase in the expression PROK1-
induced IL-8 mRNA (pb0.05; Fig. 5B) and protein (pb0.05; Fig. 5C)
compared to cells infected with NT shRNA.
4. Discussion
In the human endometrium, PROK1 expression is temporally
regulated. Expression of this factor is elevated during the window of
implantation and early pregnancy [10,12]. In the present study we
show that PROK1 induces the expression of chemokines that are
known to have angiogenic properties. We focused our attention on
studying the expression of IL-8 due to its known importance in
endometrial physiology. This chemokine is secreted by endometrial
stromal and epithelial cells in culture [29] as well as in cultured early
pregnancy decidua [30]. In vivo, IL-8 is expressed in glandular cells
and surface epithelium of the endometrium [31], where this
chemokine could be involved in several processes of endometrial
physiology such as angiogenesis, proliferation, chemotaxis, tropho-
blast invasion and uterine contraction [24].
Our results show that PROK1-PROKR1 interaction results in a
signiﬁcant induction of IL-8 in IshikawaPROKR1 cells andﬁrst trimester
decidua. Treatment of Ishikawa PROKR1 cells with PROK1 induces a
signiﬁcant increase in IL-8mRNA and protein secretion, and the activity
of its promoter is signiﬁcantly increased. The kinetics of IL-8 promoter
activity is different from the mRNA expression kinetics. While IL-8
mRNA expression levels are down to basal levels by 24 h after
treatments with PROK1 (Fig. 1D), the promoter activity is still elevated
at this time point (Supplementary Fig. 1). We believe that this
difference is explained by the fact that luciferase is a non-human
gene that can be submitted to different post-translational regulation to
that of endogenously expressed IL-8. Similarly, PROK1 induces a
signiﬁcant increase in the expression ofmRNA inﬁrst trimester decidua
where the PROKR1 and IL-8 co-localize to the epithelial compartment.
The induction of IL-8 expression by PROK1-PROKR1 interaction
occurs via activation of the calcineurin signaling pathway. Although
NF-κB has been shown to bind to the κB-like motif present in the IL-8
promoter and modulate its activity [32]; in some cases speciﬁc
inhibition of NF-κB does not impair the production of IL-8 [33]. On the
other hand, NFATc proteins have been shown to bind several
sequences that resemble binding sites for Rel family proteins [34]. In
fact, NFATc isoforms can bind to the κB-like motif in the IL-8 promoter
[35] and can modulate IL-8 promoter activity [36,37]. In Ishikawa
PROKR1 cells the modulation of IL-8 by PROK1 is independent of NF-
κB but instead modulated by the calcineurin/NFATc signaling path-
way. Interestingly, the use of an inhibitor of NF-κB resulted in a
signiﬁcant increase in the expression of IL-8. This suggests that in the
absence of basal NF-κB nuclear localization, NFAT can access more
readily the binding region in the IL-8 promoter which as mentioned
above is also recognized by NF-κB.
IL-8 promoter induction by NFAT required the presence of the
neighboring AP1 binding site, suggesting that both NFATc and AP1
transcription factors are necessary to activate the IL-8 promoter in
endometrial epithelial cells. It has been previously shown that AP1
and NFAT can mutually stabilize each other's interaction with DNA
Fig. 6. Schematic representation of PROK1 induction of RCAN1-4 and IL-8. Activation of
the PROKR1 by PROK1 results in the induction of IL-8 and RCAN1-4 expression. This
occurs via coupling of PROKR1 to Gq protein. Activation of PLCβ by Gqα results in the
production of IP3 which can then bind to IP3R in the ER and result in an efﬂux of calcium
from the ER into the cytoplasm. In addition, the opening of calcium channels in the cell
surface can also contribute to the increase in Ca2+i. This increase in Ca2+i results in
calmodulin saturation, which in turn activates calcineurin. Activated calcineurin then
dephosphorylates cytoplasmic NFAT. Dephosphorylated NFAT can then migrate to the
nucleus and bind to binding motifs in the promoter region of RCAN1-4 and IL-8 and
induce their transcription. NFAT-induced transcription of IL-8 occurs in conjunction
with AP-1. The accumulation of RCAN1-4 protein results in its binding to calcineurin and
the inhibition of NFAT dephosphorylation by calcineurin which prevents further
expression of IL-8 and RCAN1-4. Gqα=Gq protein alpha subunit, βγ=G protein beta
gamma subunits, PLCβ = phopholipase C beta, IP3 = inositol-1,4,5-triphosphate,
IP3R= IP3 receptor, ER= endoplasmic reticulum, Ca2+i= intracellular ionized calcium,
Cam = calmodulin, CnB = calcineurin regulatory subunit, CnA = calcineurin catalytic
subunit, NFAT = nuclear factor of activated T-cells, AP-1 = activator protein 1.
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transactivation to occur [38,39]. It is plausible that activation of IL-8
promoter occurs as a result of AP1 and NFAT interaction. These results
highlight the fact that activation of IL-8 promoter appears to be
differentially modulated by different transcription factor complexes
and this appears to depend on the cellular context and/or the
conditions of stimulation.
In agreement with the identiﬁcation of RCAN1 as a target gene for
PROK1 in endometrial cells by gene array analysis [10], we also show
in the present study that PROK1 treatment induced the expression of
RCAN1 mRNA and protein. Further analysis identiﬁed that PROK1
speciﬁcally induced the expression of RCAN1 isoform 4. The expres-
sion of this isoform is known to be induced by NFATc [20]. The use of
truncations and point mutated versions of RCAN1-4 promoter
together with the use of speciﬁc chemical inhibitors conﬁrmed that
the induction of RCAN1-4 by PROK1 occurs via the calcineurin/NFATc
signaling pathway.
The role of the calcineurin/NFAT signaling pathway in the PROK1-
induced expression of IL-8 was supported by the inhibitory effect
observed when RCAN1-4 was overexpressed in our model system.
Infection of Ishikawa PROKR1 cells with an adenoviral construct
containing RCAN1-4 reduced the IL-8 mRNA expression in response to
PROK1. RCAN1-4 is known to bind to calcineurin and previous studies
have shown that overexpression of this protein results in an inhibition
of calcineurin activation of NFAT [20,28]. These results also suggested
that endogenous expression of RCAN1-4 induced by PROK1 could be
playing a role as a negative modulator of the calcineurin/NFAT
pathway. This is further supported by our observation that infection of
Ishikawa PROKR1 cells with an RCAN1 shRNA lentivirus construct
resulted in a signiﬁcant reduction in the expression of RCAN1-4. This
reduction in the expression of RCAN1-4 resulted in an augmented
expression of PROK1-induced expression of IL-8.
In summary, our results show that PROK1-PROKR1 interaction
results in the activation of the calcineurin signaling pathway which in
turn induces the expression of RCAN1-4 and, in combinationwith AP1
also induces the expression of IL-8. The accumulation of RCAN1-4 then
results in the inhibition of the calcineurin signaling pathway which
causes a reduction in RCAN1-4 and IL-8 expression (Fig. 6). It is
important to remark that it has been previously demonstrated that
RCAN1-4 can itself be subject to post-translational regulation. It has
been shown that oxidative stress [40] and MAP kinase signaling [41]
can induce phosphorylation of RCAN1-4. In addition, RCAN1-4 has
been shown to stimulate the production of active GSK-3β which is
known to be involved in phosphorylation of both RCAN1-4 as well as
NFAT [42]. Phosphorylation of RCAN1-4 favors the dissociation of this
protein from calcineurin as well as promoting its degradationwhereas
phosphorylation of NFAT results in the inactivation of this transcrip-
tion factor. Therefore, it appears that the modulatory effect of RCAN1-
4 on the calcineurin/NFAT signaling pathway is itself tightly regulated.
Spatial and temporal regulation of chemokine secretion in the
endometrium is essential since these factors are involved in crucial
processes of uterine physiology such as vascular remodeling,
implantation and parturition. The involvement of PROK1 in vascular
function has been previously demonstrated [43–45]. In addition,
PROK2 via activation of PROKR1 promotes survival and angiogenesis
in cardiomyocytes [46]. The identiﬁcation of several angiogenic genes
induced by PROK1 via activation of PROKR1 [10] together with the
data presented here strongly support a role for PROK1-PROKR1 in
vascular function in the endometrium. At the same time, previous
studies in vitro have shown that RCAN1-4 is involved in the
modulation of vascular function induced by the vascular endothelial
growth factor in endothelial cells [47–49]. Our results suggest that
PROK1-PROKR1 has a role in the modulation of angiogenic events in
the endometrium in part via IL-8, and that this process could be
modulated by the action of RCAN1-4. Themodulation of IL-8 secretion
by RCAN1-4 could have an important role in the adequate regulationof secreted IL-8 in the endometriumwhichwould prevent undesirable
effects by dysregulated spatial and/or temporal synthesis of IL-8. It is
also possible that dysregulated expression of PROK1, PROKR1 or
RCAN1-4 could be involved in pathologies of vascular function of the
endometrium and in pregnancy. Further experiments in vivo are
necessary to understand the exact role of PROK1 in vascular function
in the female reproductive tract as well as the involvement of RCAN1-
4 in these processes.
Acknowledgments
We thank Sheila Wright, Nila Roy Choudhury, Stefannie McManus,
Ryan Wong and Stuart Reid from the Human Reproductive Sciences
Unit, Medical Research Council for their technical support.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.bbamcr.2009.03.008.
References
[1] M. Li, C.M. Bullock, D.J. Knauer, F.J. Ehlert, Q.Y. Zhou, Identiﬁcation of two
prokineticin cDNAs: recombinant proteins potently contract gastrointestinal
smooth muscle, Mol. Pharmacol. 59 (2001) 692–698.
1324 D. Maldonado-Pérez et al. / Biochimica et Biophysica Acta 1793 (2009) 1315–1324[2] R. Lin, J. LeCouter, J. Kowalski, N. Ferrara, Characterization of endocrine gland-
derived vascular endothelial growth factor signaling in adrenal cortex capillary
endothelial cells, J. Biol. Chem. 277 (2002) 8724–8729.
[3] J. LeCouter, C. Zlot, M. Tejada, F. Peale, N. Ferrara, Bv8 and endocrine gland-derived
vascular endothelial growth factor stimulate hematopoiesis and hematopoietic
cell mobilization, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 16813–16818.
[4] M. Dorsch, Y. Qiu, D. Soler, N. Frank, T. Duong, A. Goodearl, S. O'Neil, J. Lora, C.C.
Fraser, PK1/EG-VEGF induces monocyte differentiation and activation, J. Leukoc.
Biol. 78 (2005) 426–434.
[5] K.L. Ng, J.D. Li, M.Y. Cheng, F.M. Leslie, A.G. Lee, Q.Y. Zhou, Dependence of olfactory
bulb neurogenesis on prokineticin 2 signaling, Science 308 (2005) 1923–1927.
[6] S. Matsumoto, C. Yamazaki, K.H. Masumoto, M. Nagano, M. Naito, T. Soga, H.
Hiyama, M.Matsumoto, J. Takasaki, M. Kamohara, A. Matsuo, H. Ishii, M. Kobori, M.
Katoh, H. Matsushime, K. Furuichi, Y. Shigeyoshi, Abnormal development of the
olfactory bulb and reproductive system in mice lacking prokineticin receptor
PKR2, Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 4140–4145.
[7] D.C. Lin, C.M. Bullock, F.J. Ehlert, J.L. Chen, H. Tian, Q.Y. Zhou, Identiﬁcation and
molecular characterization of two closely related G protein-coupled receptors
activated by prokineticins/endocrine gland vascular endothelial growth factor, J.
Biol. Chem. 277 (2002) 19276–19280.
[8] T. Soga, S. Matsumoto, T. Oda, T. Saito, H. Hiyama, J. Takasaki, M. Kamohara, T.
Ohishi, H. Matsushime, K. Furuichi, Molecular cloning and characterization of
prokineticin receptors, Biochim. Biophys. Acta 1579 (2002) 173–179.
[9] W.A. Hoogerwerf, Prokineticin 1 inhibits spontaneous giant contractions in the
murine proximal colon through nitric oxide release, Neurogastroenterol. Motil. 18
(2006) 455–463.
[10] J. Evans, R.D. Catalano, K. Morgan, H.O. Critchley, R.P. Millar, H.N. Jabbour,
Prokineticin 1 signalling and gene regulation in early human pregnancy,
Endocrinology 149 (2008) 2877–2887.
[11] D. Maldonado-Perez, J. Evans, F. Denison, R.P. Millar, H.N. Jabbour, Potential roles
of the prokineticins in reproduction, Trends Endocrinol. Metab. 18 (2007) 66–72.
[12] S. Battersby, H.O. Critchley, K. Morgan, R.P. Millar, H.N. Jabbour, Expression and
regulation of the prokineticins (endocrine gland-derived vascular endothelial
growth factor and Bv8) and their receptors in the human endometrium across the
menstrual cycle, J. Clin. Endocrinol. Metab. 89 (2004) 2463–2469.
[13] E.S. Ngan, K.Y. Lee, W.S. Yeung, H.Y. Ngan, E.H. Ng, P.C. Ho, Endocrine gland-derived
vascular endothelial growth factor is expressed in human peri-implantation
endometrium, but not in endometrial carcinoma, Endocrinology 147 (2006) 88–95.
[14] C.G. Larsen, A.O. Anderson, E. Appella, J.J. Oppenheim, K. Matsushima, The
neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes,
Science 243 (1989) 1464–1466.
[15] A.E. Koch, P.J. Polverini, S.L. Kunkel, L.A. Harlow, L.A. DiPietro, V.M. Elner, S.G. Elner,
R.M. Strieter, Interleukin-8 as a macrophage-derived mediator of angiogenesis,
Science 258 (1992) 1798–1801.
[16] J. Monnier, V. Quillien, C. Piquet-Pellorce, C. Leberre, L. Preisser, H. Gascan, M.
Samson, Prokineticin 1 induces CCL4, CXCL1 and CXCL8 in human monocytes but
not in macrophages and dendritic cells, Eur. Cytokine Netw. 19 (2008) 166–175.
[17] F.C. Denison, S. Battersby, A.E. King, M. Szuber, H.N. Jabbour, Prokineticin-1: a
novel mediator of the inﬂammatory response in third-trimester human placenta,
Endocrinology 149 (2008) 3470–3477.
[18] K.J. Sales, S. Maudsley, H.N. Jabbour, Elevated prostaglandin EP2 receptor in
endometrial adenocarcinoma cells promotes vascular endothelial growth factor
expression via cyclic 3′,5′-adenosine monophosphate-mediated transactivation of
the epidermal growth factor receptor and extracellular signal-regulated kinase
1/2 signaling pathways, Mol. Endocrinol. 18 (2004) 1533–1545.
[19] F.C. Denison, S.C. Riley, N.C. Wathen, T. Chard, A.A. Calder, R.W. Kelly, Differential
concentrations of monocyte chemotactic protein-1 and interleukin-8 within the
ﬂuid compartments present during the ﬁrst trimester of pregnancy, Hum. Reprod.
13 (1998) 2292–2295.
[20] T. Minami, K. Horiuchi, M. Miura, M.R. Abid,W. Takabe, N. Noguchi, T. Kohro, X. Ge,
H. Aburatani, T. Hamakubo, T. Kodama, W.C. Aird, Vascular endothelial growth
factor- and thrombin-induced termination factor, Down syndrome critical region-
1, attenuates endothelial cell proliferation and angiogenesis, J. Biol. Chem. 279
(2004) 50537–50554.
[21] A. Casola, R.P. Garofalo, M. Jamaluddin, S. Vlahopoulos, A.R. Brasier, Requirement
of a novel upstream response element in respiratory syncytial virus-induced IL-8
gene expression, J. Immunol. 164 (2000) 5944–5951.
[22] C.R. Bush, J.M. Havens, B.M. Necela, W. Su, L. Chen, M. Yanagisawa, P.Z.
Anastasiadis, R. Guerra, B.A. Luxon, E.A. Thompson, Functional genomic analysis
reveals cross-talk between peroxisome proliferator-activated receptor gamma
and calcium signaling in human colorectal cancer cells, J. Biol. Chem. 282 (2007)
23387–23401.
[23] M. Nishida, The Ishikawa cells from birth to the present, Hum. Cell 15 (2002)
104–117.
[24] U.A. Kayisli, N.G. Mahutte, A. Arici, Uterine chemokines in reproductive physiology
and pathology, Am. J. Reprod. Immunol. 47 (2002) 213–221.
[25] K.J. Davies, G. Ermak, B.A. Rothermel, M. Pritchard, J. Heitman, J. Ahnn, F.
Henrique-Silva, D. Crawford, S. Canaider, P. Strippoli, P. Carinci, K.T. Min, D.S. Fox,
K.W. Cunningham, R. Bassel-Duby, E.N. Olson, Z. Zhang, R.S. Williams, H.P. Gerber,
M. Perez-Riba, H. Seo, X. Cao, C.B. Klee, J.M. Redondo, L.J. Maltais, E.A. Bruford, S.Povey, J.D. Molkentin, F.D. McKeon, E.J. Duh, G.R. Crabtree, M.S. Cyert, S. de la Luna,
X. Estivill, Renaming the DSCR1/Adapt78 gene family as RCAN: regulators of
calcineurin, FASEB J. 21 (2007) 3023–3028.
[26] E. Bush, J. Fielitz, L. Melvin, M. Martinez-Arnold, T.A. McKinsey, R. Plichta, E.N.
Olson, A small molecular activator of cardiac hypertrophy uncovered in a chemical
screen formodiﬁers of the calcineurin signaling pathway, Proc. Natl. Acad. Sci. U. S.
A. 101 (2004) 2870–2875.
[27] J. Yang, B. Rothermel, R.B. Vega, N. Frey, T.A. McKinsey, E.N. Olson, R. Bassel-Duby,
R.S. Williams, Independent signals control expression of the calcineurin inhibitory
proteins MCIP1 and MCIP2 in striated muscles, Circ. Res. 87 (2000) E61–68.
[28] B. Chan, G. Greenan, F. McKeon, T. Ellenberger, Identiﬁcation of a peptide fragment
of DSCR1 that competitively inhibits calcineurin activity in vitro and in vivo, Proc.
Natl. Acad. Sci. U. S. A. 102 (2005) 13075–13080.
[29] A. Arici, J.R. Head, P.C. MacDonald, M.L. Casey, Regulation of interleukin-8 gene
expression in human endometrial cells in culture, Mol. Cell. Endocrinol. 94 (1993)
195–204.
[30] S. Engert, L. Rieger, M. Kapp, J.C. Becker, J. Dietl, U. Kammerer, Proﬁling
chemokines, cytokines and growth factors in human early pregnancy decidua
by protein array, Am. J. Reprod. Immunol. 58 (2007) 129–137.
[31] A. Arici, E. Seli, L.M. Senturk, L.S. Gutierrez, E. Oral, H.S. Taylor, Interleukin-8 in the
human endometrium, J. Clin. Endocrinol. Metab. 83 (1998) 1783–1787.
[32] C. Kunsch, C.A. Rosen, NF-kappa B subunit-speciﬁc regulation of the interleukin-8
promoter, Mol. Cell. Biol. 13 (1993) 6137–6146.
[33] C. Lambert, J. Li, K. Jonscher, T.C. Yang, P. Reigan, M. Quintana, J. Harvey, B.M. Freed,
Acrolein inhibits cytokine gene expression by alkylating cysteine and arginine
residues in the NF-kappaB1 DNA binding domain, J. Biol. Chem. 282 (2007)
19666–19675.
[34] A. Rao, C. Luo, P.G. Hogan, Transcription factors of the NFAT family: regulation and
function, Annu. Rev. Immunol. 15 (1997) 707–747.
[35] L. Jin, P. Sliz, L. Chen, F. Macian, A. Rao, P.G. Hogan, S.C. Harrison, An asymmetric
NFAT1 dimer on a pseudo-palindromic kappa B-like DNA site, Nat. Struct. Biol. 10
(2003) 807–811.
[36] S. Okamoto, N. Mukaida, K. Yasumoto, N. Rice, Y. Ishikawa, H. Horiguchi, S.
Murakami, K. Matsushima, The interleukin-8 AP-1 and kappa B-like sites are
genetic end targets of FK506-sensitive pathway accompanied by calcium
mobilization, J. Biol. Chem. 269 (1994) 8582–8589.
[37] V. Boss, X. Wang, L.F. Koppelman, K. Xu, T.J. Murphy, Histamine induces nuclear
factor of activated T cell-mediated transcription and cyclosporin A-sensitive
interleukin-8 mRNA expression in human umbilical vein endothelial cells, Mol.
Pharmacol. 54 (1998) 264–272.
[38] F. Macian, C. Lopez-Rodriguez, A. Rao, Partners in transcription: NFAT and AP-1,
Oncogene 20 (2001) 2476–2489.
[39] L.J. Sun, B.R. Peterson, G.L. Verdine, Dual role of the nuclear factor of activated T
cells insert region in DNA recognition and cooperative contacts to activator
protein 1, Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4919–4924.
[40] A.V. Narayan, R. Stadel, A.B. Hahn, D.L. Bhoiwala, G. Cornielle, E. Sarazin, I. Koleilat,
D.R. Crawford, Redox response of the endogenous calcineurin inhibitor Adapt 78,
Free Radic. Biol. Med. 39 (2005) 719–727.
[41] S.Y. Shin, S.M. Choo, D. Kim, S.J. Baek, O. Wolkenhauer, K.H. Cho, Switching
feedbackmechanisms realize the dual role of MCIP in the regulation of calcineurin
activity, FEBS Lett. 580 (2006) 5965–5973.
[42] G. Ermak, C.D. Harris, D. Battocchio, K.J. Davies, RCAN1 (DSCR1 or Adapt78)
stimulates expression of GSK-3beta, FEBS J. 273 (2006) 2100–2109.
[43] J. LeCouter, J. Kowalski, J. Foster, P. Hass, Z. Zhang, L. Dillard-Telm, G. Frantz, L.
Rangell, L. DeGuzman, G.A. Keller, F. Peale, A. Gurney, K.J. Hillan, N. Ferrara,
Identiﬁcation of an angiogenic mitogen selective for endocrine gland endothe-
lium, Nature 412 (2001) 877–884.
[44] M. Samson, F.V. Peale Jr., G. Frantz, N. Rioux-Leclercq, E. Rajpert-De Meyts, N.
Ferrara, Human endocrine gland-derived vascular endothelial growth factor:
expression early in development and in Leydig cell tumors suggests roles in
normal and pathological testis angiogenesis, J. Clin. Endocrinol. Metab. 89 (2004)
4078–4088.
[45] T. Goi, M. Fujioka, Y. Satoh, S. Tabata, K. Koneri, H. Nagano, Y. Hirono, K. Katayama,
K. Hirose, A. Yamaguchi, Angiogenesis and tumor proliferation/metastasis of
human colorectal cancer cell line SW620 transfected with endocrine glands-
derived-vascular endothelial growth factor, as a new angiogenic factor, Cancer
Res. 64 (2004) 1906–1910.
[46] K. Urayama, C. Guilini, N. Messaddeq, K. Hu, M. Steenman, H. Kurose, G. Ert, C.G.
Nebigil, The prokineticin receptor-1 (GPR73) promotes cardiomyocyte survival
and angiogenesis, FASEB J. 21 (2007) 2980–2993.
[47] B.A. Hesser, X.H. Liang, G. Camenisch, S. Yang, D.A. Lewin, R. Scheller, N. Ferrara, H.
P. Gerber, Down syndrome critical region protein 1 (DSCR1), a novel VEGF target
gene that regulates expression of inﬂammatory markers on activated endothelial
cells, Blood 104 (2004) 149–158.
[48] M. Iizuka, M. Abe, K. Shiiba, I. Sasaki, Y. Sato, Down syndrome candidate region 1,a
downstream target of VEGF, participates in endothelial cell migration and
angiogenesis, J. Vasc. Res. 41 (2004) 334–344.
[49] L. Qin, D. Zhao, X. Liu, J.A. Nagy, M.V. Hoang, L.F. Brown, H.F. Dvorak, H. Zeng, Down
syndrome candidate region 1 isoform 1 mediates angiogenesis through the
calcineurin-NFAT pathway, Mol. Cancer Res. 4 (2006) 811–820.
